Welcome to Elaprase.com. ELAPRASE (idursulfase) is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II)

ELAPRASE® (idursulfase) is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older.

In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.

The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age.

Discover ELAPRASE Get Product Support & Assistance

How Does

ELAPRASE is designed to replace I2S, the enzyme that is deficient or absent in people with Hunter syndrome.


Questions About

Contact OnePath® for product support, insurance help, co-pay assistance and more.


Product Support and Reimbursement

Get key facts and learn how to get assistance with insurance coverage for ELAPRASE.